Intellia Thera CS stocks price quote with latest real-time prices, charts, financials, latest news, technical analysis and opinions. Exploring Intellia Therapeutics (NASDAQ:NTLA) stock? View NTLA's stock price, price target, earnings, financials, forecast, insider trades, news, and SEC filings View Intellia Therapeutics, Inc. NTLA investment & stock information. Get the latest Intellia Therapeutics, Inc. NTLA detailed stock quotes, stock data, Real-Time View today's stock price, news and analysis for Intellia Therapeutics Inc. (NTLA). Barron's also provides information on historical stock ratings, target prices, Get today's Intellia Therapeutics Inc stock price and latest NTLA news as well as Intellia Therapeutics Inc real-time stock quotes, technical analysis, full financials
is calculated by multiplying the current stock price by the number of shares outstanding. Intellia Therapeutics market cap as of December 30, 2019 is $0.72B.
12 Mar 2019 Intellia Therapeutics, Inc. (NASDAQ:NTLA) shareholders should be happy to see the share price up 23% in the last month. But that's not NTLA Intellia Therapeutics, Inc. daily Stock Chart Book/sh, 5.68, P/B, 2.58, EPS next Y, -15.70%, ROA, -26.00%, Target Price, 28.05, Perf Year, 7.47%. Cash/ Stock Quote · Stock Chart · Historical Price Lookup · Investment Calculator. stock information. Stock Quote. NASDAQ: NTLA. $15.38. Dec 27, 2019 4:00 PM EST. IPO Status Public Stock Symbol NASDAQ:NTLA Company Type For Profit Money Raised at IPO $108M IPO Share Price $22.00 IPO Date May 6, 2016. 14 Nov 2019 (NYSE: PING) shares rose 17.5% to $19.39 in pre-market trading after the Inc. (NASDAQ: NTLA) fell 3.1% to $13.51 in pre-market trading. 25 Feb 2019 Editas Medicine (EDIT) and Intellia Therapeutics (NTLA) stocks rose 5.3% The rating tracks market leadership by showing how a stock's price
5 Dec 2019 Stay Ahead of Wall Street. Find out what is happening to Intellia Therapeutics, Inc. (NASDAQ:NTLA) stock today? Its price is jumping 0.51
In depth view into NTLA (Intellia Therapeutics) stock including the latest price, news, dividend history, earnings information and financials.
There’s a pretty violent reaction in ABEO, following a short seller report by Mako Research on SeekingAlpha: http://seekingalpha.com/article/4029813-abeona-stock-promotions-fraud-convictions-demonstrably-unviable-science-sell-95-percent
Investment Outlook Intellia Therapeutics, Inc. has a fundamental score of 67 and has a relative valuation of OVERVALUED. Intellia Therapeutics, Inc. (NASDAQ:NTLA) is currently trading lower than its price target which is set to $30.81 by the analyst. The stock is -55.3% Below its 1-Year High which is $32.95. NTLA has a difference of 33.53% from its 1 year low which stands at $11.03. The company is currently rated by analyst who are keeping a close eye on the 11/26/2019 · CAMBRIDGE, Mass., Nov. 26, 2019 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused on developing Stay on top of the changing U.S. and global markets with our market summary page. Dive deeper with our rich data, rate tables and tools. Detailed peer (competitor) analysis for NASDAQ:NTLA Intellia Therapeutics, Inc.
View today's stock price, news and analysis for Intellia Therapeutics Inc. (NTLA). Barron's also provides information on historical stock ratings, target prices,
27 Dec 2019 Intellia Therapeutics, Inc. is a genome editing company. The Company is focused on developing therapeutics utilizing a biological tool known
Premarket-300x245 Friday April 13, 2018, Today Stock Market Also in the penny stock arena, we did well with RNVA this week, including it in Tuesday’s premarket report. From a subpenny low of .006, the stock made a 200% move to yesterday’s high of .018, and it’s gone even higher in the premarket this… Nektar Therapeutics (NKTR) stock rallied, reaching all-time high with positive results in every aspect of the firm’s fundamentals from reported finances, to reported products’ results, etc., Cash and investments in marketable securities at… From that point, the stock has made a very nice move in just a short time. Some investors are selling AGEN in premarket trading for a reason that might be unimportant anymore with Agenus’ totally changed status now with its new immunotherapy pipeline.